Owkin announced an agreement on September 11, 2026, to license K Pro, its AI scientist for biopharma research, together with multimodal patient data to Servier, an independent international pharmaceutical group governed by a foundation, to advance Servier’s oncology research. What the License Covers Under the agreement, Owkin will make multimodal patient data from its MOSAIC network accessible for analysis to Servier’s research teams within K Pro. The announcement, datelined New York and Paris…